策划“自问自答”！英集芯，被立案调查！

Core Viewpoint - Shenzhen Injoinic Technology Co., Ltd. (referred to as "Injoinic") is under investigation by the China Securities Regulatory Commission (CSRC) for misleading statements regarding its information disclosure practices [1][2]. Group 1: Regulatory Actions - On January 6, Injoinic was found to have made misleading statements on the Shanghai Stock Exchange's E-interaction platform, leading to a CSRC investigation [1]. - The CSRC issued a notice of investigation to Injoinic on February 13, 2026, due to suspected violations of information disclosure laws [1]. - The Shanghai Stock Exchange has issued a regulatory warning to Injoinic and its responsible personnel for failing to accurately disclose the status and sales scale of its IPA1299 chip product [2][3]. Group 2: Product and Market Impact - Injoinic claimed that its IPA1299 chip, designed for high-precision measurement of human bioelectric signals, had entered mass production and could compete with leading overseas products [2]. - However, the company later clarified that the IPA1299 chip is still in the market cultivation phase and has not yet achieved significant sales, indicating uncertainty in future sales performance [2][3]. - The application of the IPA1299 chip in non-invasive brain-machine interface technology differs significantly from existing invasive technologies, highlighting a gap in technological pathways [2]. Group 3: Financial Performance - Injoinic reported a total operating revenue of 161.15 million yuan for the fiscal year 2025, representing a year-on-year increase of 12.65% [4]. - The net profit attributable to the parent company was 17.74 million yuan, reflecting a 42.81% increase compared to the previous year [4]. - The net profit after deducting non-recurring gains and losses was 16.17 million yuan, marking a 45.92% year-on-year growth [4].